Vermersch P, et al. The EXPAND Study Results: Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis. EAN 2017, O1217.
Rabobank investeert 3 miljoen in ALS Investment Fund
nov 2017 | Neuro-musculair
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen